ReviewCurrent opinion in virology2016
Antiviral targets of human noroviruses.
Review in Current opinion in virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Norovirus replication, host interactions and vaccine advances.Nature reviews. Microbiology · 2025Review
- Article
- In Vitro Culture of Human Norovirus in the Last 20 Years.Biomedicines · 2024Review
- Article
- Structural Investigations on Novel Non-Nucleoside Inhibitors of Human Norovirus Polymerase.Viruses · 2022Article
- Atomic structure of the predominant GII.4 human norovirus capsid reveals novel stability and plasticity.Nature communications · 2022Article
- Predicting New Anti-Norovirus Inhibitor With the Help of Machine Learning Algorithms and Molecular Dynamics Simulation-Based Model.Frontiers in chemistry · 2021Article
- Chemical-Shift Perturbations Reflect Bile Acid Binding to Norovirus Coat Protein: Recognition Comes in Different Flavors.Chembiochem : a European journal of chemical biology · 2020Article
- A Secreted Viral Nonstructural Protein Determines Intestinal Norovirus Pathogenesis.Cell host & microbe · 2019Article
- Norovirus antivirals: Where are we now?Medicinal research reviews · 2019Review
- Genetic characterization of norovirus GII.4 variants circulating in Canada using a metagenomic technique.BMC infectious diseases · 2018Article
- Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors.Bioorganic & medicinal chemistry letters · 2018Article
- Prophylactic efficacy of orally administered Bacillus poly-γ-glutamic acid, a non-LPS TLR4 ligand, against norovirus infection in mice.Scientific reports · 2018Article
- Norovirus Illnesses in Children and Adolescents.Infectious disease clinics of North America · 2018Review
- Structure-guided design, synthesis and evaluation of oxazolidinone-based inhibitors of norovirus 3CL protease.European journal of medicinal chemistry · 2018Article
- Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.Current drug metabolism · 2018Review
- Structural features of glycan recognition among viral pathogens.Current opinion in structural biology · 2017Review
- Design, synthesis, and evaluation of a novel series of macrocyclic inhibitors of norovirus 3CL protease.European journal of medicinal chemistry · 2017Article
- Structure-based exploration and exploitation of the SEuropean journal of medicinal chemistry · 2017Article
- Recent advances in understanding noroviruses.F1000Research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Human noroviruses are major causative agents of sporadic and epidemic gastroenteritis both in children and adults. Currently there are no licensed therapeutic intervention measures either in terms of vaccines or drugs available for these highly contagious human pathogens. Genetic and antigenic diversity of these viruses, rapid emergence of new strains, and their ability to infect a broad population by using polymorphic histo-blood group antigens for cell attachment, pose significant challenges for the development of effective antiviral agents. Despite these impediments, there is progress in the design and development of therapeutic agents. These include capsid-based candidate vaccines, and potential antivirals either in the form of glycomimetics or designer antibodies that block HBGA binding, as well as those that target essential non-structural proteins such as the viral protease and RNA-dependent RNA polymerase. In addition to these classical approaches, recent studies suggest the possibility of interferons and targeting host cell factors as viable approaches to counter norovirus infection. This review provides a brief overview of this progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.